AstraZeneca removes Zoladex 3.6mg from Australian PBS and private market, affecting breast cancer/endometriosis patients
Consensus Summary
AstraZeneca will remove Zoladex 3.6mg, a critical hormone therapy for breast cancer and endometriosis, from Australia’s PBS and private market starting November 2026, citing commercial reasons. The drug, used by an estimated 8,600 patients in early 2026, suppresses estrogen to slow cancer growth and manage endometriosis. AstraZeneca will offer free access for six months to those without alternatives, while the higher-dose 10.8mg version (currently PBS-listed for prostate cancer) may be expanded for breast cancer patients. Patient advocacy groups and health authorities are concerned about unmet clinical needs, with delays in listing other breast cancer drugs on the PBS. The decision reflects broader tensions between Australia’s PBS pricing model and global pharmaceutical company strategies, as seen in Eli Lilly’s refusal to list Mounjaro due to low reimbursement rates.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Zoladex 3.6mg (Goserelin 3.6mg implant) will be removed from the Australian PBS and private market from November 2026
- AstraZeneca cited 'commercial reasons' for the removal, stating it is a global decision to reduce dose options in some countries
- The drug is used to slow breast cancer growth, reduce recurrence risk, and manage endometriosis by suppressing ovarian estrogen production
- AstraZeneca will provide free access to Zoladex 3.6mg for six months for patients without alternative treatment pathways
- The higher-dose Zoladex 10.8mg (approved for prostate cancer) remains on the PBS, with potential future approval for breast cancer patients
- An estimated 8,600 patients were dispensed Zoladex 3.6mg in the first three months of 2026
Points of Difference
Details reported by only one source:
- Kate Hardman, a 41-year-old stage 4 metastatic breast cancer patient, has used Zoladex 3.6mg since 2023 and called the decision 'cruel' and 'soul-destroying'
- Vicki Durston, director of policy advocacy at Breast Cancer Network Australia, stated patients are 'living with fear of recurrence or progression'
- The Pharmaceutical Benefits Advisory Committee (PBAC) warned the removal would result in 'unmet clinical need'
- Senator David Pocock questioned health department officials, who confirmed AstraZeneca’s decision was commercial and not safety-related
- Nial Wheate, a Macquarie University professor, noted the PBS costs the government billions annually and requires strong negotiations with drug companies
- AstraZeneca declined to specify which other countries were affected by the dose removal
- The 10.8mg dose is currently only PBS-listed for prostate cancer, with PBAC likely to consider expanding its approval for breast cancer in July 2026
- Clinical oncologist Rachel Dear expressed hope for the 10.8mg dose approval but noted uncertainty about its efficacy as a 'gold standard' for all patients
- Eli Lilly recently refused to list Mounjaro on the PBS, citing low pricing as a key grievance
- Breast Cancer Network Australia highlighted increasing delays in listing critical breast cancer drugs on the PBS, linked to US policy changes and global uncertainty
Contradictions
Conflicting information between sources:
- The ABC states AstraZeneca provided no additional context after questions about the global decision, while the Guardian does not mention this lack of detail
Source Articles
Lifesaving breast cancer and endometriosis drug to be pulled from shelves
Patients have been left frustrated and scared after learning that a life-saving breast cancer and endometriosis drug is to be pulled from shelves in Australia and some other countries.
Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?
The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment Get our breaking news email , free app or daily news podcast Thousands of women could be left without vital breast cancer and endometriosis medicine when AstraZeneca removes its treatment from the Pharmaceutical Benefits Scheme (PBS) and the private market, experts warn. Zoladex will no longer be available in Australia from November, as the ABC first reported , but